Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 2Thoracic 1Genitourinary 1Dermatologic 1

Conditions

Melanoma 3Somatostatinoma 1Pheochromocytoma 1Insulinoma 1Glucagonoma 1Gastrinoma 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Merkel Cell 1Carcinoma, Medullary 1Carcinoma, Islet Cell 1

Interventions

Everolimus 2veliparib 1vatalanib 1pentetreotide 1cixutumumab 1antineoplaston AS 2-1 1antineoplaston A10 1Temozolomide 1Specimen Handling 1Salts 1Octreotide 1Nivolumab 1Melphalan 1Magnetic Resonance Spectroscopy 1Ipilimumab 1High-Energy Shock Waves 1Fentanyl 1Complementary Therapies 1Capecitabine 1CTLA-4 Antigen 1Blood Specimen Collection 1Biological Therapy 1Acetates 190Y-octreotide, DOTA-Tyr(3)- 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Somatostatinoma × vatalanib × Dermatologic × Clear all
NCT00655655 2024-08-21

Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors

Mayo Clinic

Phase 1 Completed
96 enrolled
DermatologicEndocrineGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Glucagonoma, Insulinoma, Melanoma, Pheochromocytoma, Somatostatinoma, Carcinoma, Merkel Cell, Gastrinoma, Carcinoma, Islet Cell, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡